Detalhe da pesquisa
1.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38112922
2.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34125340
3.
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
BMC Cancer
; 20(1): 783, 2020 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32819305
4.
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
JAMA
; 317(1): 37-47, 2017 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27918780
5.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
J Clin Oncol
; 41(10): 1830-1840, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720083
6.
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer
; 152: 127-134, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387727
7.
First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
JAMA Oncol
; 1(9): 1272-80, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26378637